{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T14:42:28Z","timestamp":1720276948682},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Roche diagnostics"}],"content-domain":{"domain":["journalofclinicalvirology.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.jcv.2016.02.022","type":"journal-article","created":{"date-parts":[[2016,2,27]],"date-time":"2016-02-27T12:18:37Z","timestamp":1456575517000},"page":"36-43","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Clinical relevance of the HCV protease inhibitor-resistant mutant viral load assessed by ultra-deep pyrosequencing in treatment failure"],"prefix":"10.1016","volume":"78","author":[{"given":"Sofiane","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Bourliere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Souad","family":"Benali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Oules","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Castellani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hac\u00e8ne","family":"Khiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Camus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Penaranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Chiche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitri","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chalom","family":"Sayada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Olive","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Halfon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.jcv.2016.02.022_bib0005","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.jcv.2016.02.022_bib0010","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.jcv.2016.02.022_bib0015","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/j.1478-3231.2012.02856.x","article-title":"Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver","volume":"32","author":"Leroy","year":"2012","journal-title":"Liver Int."},{"issue":"11","key":"10.1016\/j.jcv.2016.02.022_bib0020","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response-guided telaprevir combination treatment for hepatitis C virus infection","volume":"365","author":"Sherman","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.jcv.2016.02.022_bib0025","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.jcv.2016.02.022_bib0030","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.jcv.2016.02.022_bib0035","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/liv.12423","article-title":"HCV direct-acting antiviral agents: the best interferon-free combinations","volume":"34","author":"Schinazi","year":"2014","journal-title":"Liver Int."},{"issue":"8","key":"10.1016\/j.jcv.2016.02.022_bib0040","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1001\/jama.2013.109309","article-title":"Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial","volume":"310","author":"Osinusi","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jcv.2016.02.022_bib0045","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1517\/14656566.2014.857656","article-title":"Sofosbuvir for the treatment of hepatitis C virus","volume":"15","author":"Asselah","year":"2014","journal-title":"Expert Opin. Pharmacother."},{"issue":"2","key":"10.1016\/j.jcv.2016.02.022_bib0050","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jhep.2014.05.001","volume":"61","author":"EASL recommendations on treatment of hepatitis C","year":"2014","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.jcv.2016.02.022_bib0055","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jhep.2011.01.011","article-title":"C virus resistance to protease inhibitors","volume":"55","author":"Halfon","year":"2011","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.jcv.2016.02.022_bib0060","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3851\/IMP2632","article-title":"Dynamic and rapid changes in viral quasispecies by UDPS in chronic hepatitis C patients receiving telaprevir-based therapy","volume":"18","author":"Trimoulet","year":"2013","journal-title":"Antivir. Ther."},{"issue":"15","key":"10.1016\/j.jcv.2016.02.022_bib0065","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1097\/QAD.0b013e32830e4cd8","article-title":"Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa","volume":"22","author":"Mee","year":"2008","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.jcv.2016.02.022_bib0070","doi-asserted-by":"crossref","first-page":"e34372","DOI":"10.1371\/journal.pone.0034372","article-title":"Hepatitis C viral evolution in genotype 1 treatment-naive and treatment-experienced patients receiving telaprevir-based therapy in clinical trials","volume":"7","author":"Kieffer","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jcv.2016.02.022_bib0075","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1128\/AAC.01452-09","article-title":"In vitro resistance profile of the hepatitis C virus NS3\/4A protease inhibitor TMC435","volume":"54","author":"Lenz","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.jcv.2016.02.022_bib0080","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1002\/hep.23192","article-title":"Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients","volume":"50","author":"Susser","year":"2009","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.jcv.2016.02.022_bib0085","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1097\/QAD.0000000000000267","article-title":"Comparison of ultra-deep versus Sanger sequencing detection of minority mutations on the HIV-1 drug resistance interpretations after virological failure","volume":"28","author":"Mohamed","year":"2014","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.jcv.2016.02.022_bib0090","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1086\/591141","article-title":"Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects","volume":"198","author":"Bartels","year":"2008","journal-title":"J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.jcv.2016.02.022_bib0095","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1365-2893.2011.01449.x","article-title":"Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b","volume":"19","author":"Vermehren","year":"2012","journal-title":"J. Viral Hepat."},{"issue":"11","key":"10.1016\/j.jcv.2016.02.022_bib0100","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1128\/JVI.02778-12","article-title":"Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients","volume":"87","author":"Dietz","year":"2013","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.jcv.2016.02.022_bib0105","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1128\/JCM.05842-11","article-title":"Specific detection of naturally occurring hepatitis C virus mutants with resistance to telaprevir and boceprevir (protease inhibitors) among treatment-naive infected individuals","volume":"50","author":"Fonseca-Coronado","year":"2012","journal-title":"J. Clin. Microbiol."},{"issue":"9","key":"10.1016\/j.jcv.2016.02.022_bib0110","doi-asserted-by":"crossref","first-page":"e24907","DOI":"10.1371\/journal.pone.0024907","article-title":"Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing","volume":"6","author":"Nasu","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jcv.2016.02.022_bib0115","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jcv.2011.08.015","article-title":"Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir","volume":"52","author":"Susser","year":"2011","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2016.02.022_bib0120","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiu340","article-title":"Deep-sequencing analysis of the gene encoding the hepatitis C Virus nonstructural 3-4A protease confirms a low prevalence of telaprevir-resistant variants at baseline and the end of the REALIZE study","author":"Dierynck","year":"2014","journal-title":"J. Infect. Dis."},{"issue":"7","key":"10.1016\/j.jcv.2016.02.022_bib0125","doi-asserted-by":"crossref","first-page":"e41191","DOI":"10.1371\/journal.pone.0041191","article-title":"Evaluation of persistence of resistant variants with ultra-deep pyrosequencing in chronic hepatitis C patients treated with telaprevir","volume":"7","author":"Thomas","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jcv.2016.02.022_bib0130","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/jvh.12230","article-title":"Importance of HCV genotype 1 subtypes for drug resistance and response to therapy","volume":"21","author":"Wyles","year":"2014","journal-title":"J. Viral Hepat."},{"issue":"7","key":"10.1016\/j.jcv.2016.02.022_bib0135","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1128\/JCM.03633-14","article-title":"Naturally occurring resistance-associated variants of hepatitis C virus protease inhibitors in poor responders to pegylated interferon-ribavirin","volume":"53","author":"Larrat","year":"2015","journal-title":"J. Clin. Microbiol."}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653216300142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653216300142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T20:57:58Z","timestamp":1536958678000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653216300142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":27,"alternative-id":["S1386653216300142"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2016.02.022","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical relevance of the HCV protease inhibitor-resistant mutant viral load assessed by ultra-deep pyrosequencing in treatment failure","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2016.02.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}